More Company News

Avacta

H123 interim results
28 Sep 2023Read More

Avacta

Completion of AVA6000 sixth dose escalation and clinical update
19 Sep 2023Read More

Avacta

Completion of fifth dose escalation of AVA6000
21 Jun 2023Read More

Avacta

Second milestone in AffyXell JV
05 Jun 2023Read More

Avacta

Aquisition of Coris Bioconcept
01 Jun 2023Read More

Avacta

First patient dosed in the US in AVA6000 Phase I study
27 Apr 2023Read More

Avacta

FY22 results
25 Apr 2023Read More

Avacta

AVA3996 data poster presented at AACR
17 Apr 2023Read More

Avacta

First US clinical investigator AVA6000 sites opened
06 Apr 2023Read More

Avacta

First patient dosed in fifth cohort of AVA6000 Phase I study
05 Apr 2023Read More

1 2 3 4 5
Return to Avacta
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).